LENZ Therapeutics and Théa Ink $70M Deal for LNZ100 Eye Drop Commercialization in Canada

Reuters
07 Jul
LENZ <a href="https://laohu8.com/S/LENZ">Therapeutics</a> and Théa Ink $70M Deal for LNZ100 Eye Drop Commercialization in Canada

LENZ Therapeutics, Inc. has entered into an exclusive license and commercialization agreement with Laboratoires Théa for the Canadian market, focusing on the eye drop treatment LNZ100 for presbyopia. The agreement secures over $70 million in upfront and milestone payments for LENZ, along with double-digit royalties on net sales. Théa, a prominent company in eye-care product commercialization, will handle the development, manufacturing, registration, and marketing of LNZ100 in Canada. This partnership marks LENZ's third international commercialization deal for LNZ100, underscoring its commitment to broadening patient access to this innovative therapy globally. Jean-Frédéric Chibret, President of Théa, highlighted the potential of this promising treatment to address a widespread condition affecting millions of adults in Canada.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lenz Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9489265-en) on July 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10